A Study of IBI362 in Chinese Patients With Type 2 Diabetes

Summary

The purpose of this study is to evaluate the efficacy and safety of IBI362 in Chinese patients with Type 2 Diabetes.

Timeline

Start

2021-09-06

Primary completion

2022-04-28

Completion

2022-06-11

Outcome

Met primary endpoint

paper with mazdutide (-1.35% with dulaglutide and 0.03% with placebo; all P < 0.0001 vs. placebo). PMID 37943529 ↗

release “The phase 2 study of mazdutide in Chinese patients with type 2 diabetes met the primary endpoint.” innoventbio.com ↗

Publications

• Zhang B, Cheng Z, Chen J, Zhang X, Liu D, Jiang H, Ma G, Wang X, Gan S, Sun J, Jin P, Yi J, Shi B, Ma J, Ye S, Wang G, Ji L, Gu X, Yu T, An P, Deng H, Li H, Li L, Ma Q, Qian L, Yang W. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes Care. 2024 Jan 1;47(1):160-168. doi: 10.2337/dc23-1287.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mazdutide	Protein / enzyme biologic	3 mg	Subcutaneous
Subject	Mazdutide	Protein / enzyme biologic	4.5 mg	Subcutaneous
Subject	Mazdutide	Protein / enzyme biologic	6 mg	Subcutaneous

Indications